Inventiva Secures Up to €348 Million in Financing to Advance Lanifibranor for MASH Treatment

Financing Amount:
Inventiva has secured up to €348 million ($380 million) in financing to advance the Phase 3 NATiV3 clinical trial for lanifibranor, a treatment for MASH.

Initial Funding:
The company received an initial amount of €94.1 million ($103.4 million) from the multi-tranche equity financing, with the remaining funds to be distributed in subsequent phases.

Milestone Payments:
Inventiva also secured up to $30 million in milestone payments through an amendment to the license and collaboration agreement with CTTQ.

Clinical Trial Progress:
Over 1,100 patients have been randomized in the NATiV3 study, with completion of enrollment projected in the first half of 2025.

Board Appointments:
Mark Pruzanski, MD, has been appointed as Chairman, and Srinivas Akkaraju, MD, PhD, as a director, subject to shareholder approval at the next General Meeting.

Investor Confidence:
The financing reflects the confidence of participating investors and CTTQ in lanifibranor’s potential as a breakthrough therapy for MASH patients.

Market Potential:
The MASH market is forecasted to reach $25.7 billion by 2032 across seven major markets, including the US, France, Germany, Italy, Spain, the UK, and Japan.